NASDAQ:OHRP - OHR Pharmaceutical Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.25 +0.01 (+0.45 %) (As of 03/25/2019 02:47 PM ET)Previous Close$2.24Today's Range$2.15 - $2.2552-Week Range$1.60 - $6.60Volume32,206 shsAverage Volume388,798 shsMarket Capitalization$6.37 millionP/E RatioN/ADividend YieldN/ABeta1.2 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email OHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York. Receive OHRP News and Ratings via Email Sign-up to receive the latest news and ratings for OHRP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OHRP Previous Symbol CUSIPN/A CIK1173281 Webwww.ohrpharmaceutical.com Phone212-682-8452Debt Debt-to-Equity RatioN/A Current Ratio5.44 Quick Ratio5.44Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.86 per share Price / Book0.58Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-13,230,000.00 Net MarginsN/A Return on Equity-74.77% Return on Assets-69.84%Miscellaneous EmployeesN/A Outstanding Shares2,830,000Market Cap$6.37 million Next Earnings Date5/21/2019 (Estimated) OptionableOptionable OHR Pharmaceutical (NASDAQ:OHRP) Frequently Asked Questions What is OHR Pharmaceutical's stock symbol? OHR Pharmaceutical trades on the NASDAQ under the ticker symbol "OHRP." When did OHR Pharmaceutical's stock split? How did OHR Pharmaceutical's stock split work? OHR Pharmaceutical shares reverse split before market open on Monday, February 4th 2019. The 1-20 reverse split was announced on Wednesday, January 23rd 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 1st 2019. An investor that had 100 shares of OHR Pharmaceutical stock prior to the reverse split would have 5 shares after the split. How were OHR Pharmaceutical's earnings last quarter? OHR Pharmaceutical Inc (NASDAQ:OHRP) announced its quarterly earnings data on Thursday, February, 14th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter. View OHR Pharmaceutical's Earnings History. When is OHR Pharmaceutical's next earnings date? OHR Pharmaceutical is scheduled to release their next quarterly earnings announcement on Tuesday, May 21st 2019. View Earnings Estimates for OHR Pharmaceutical. Has OHR Pharmaceutical been receiving favorable news coverage? Media headlines about OHRP stock have been trending positive recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. OHR Pharmaceutical earned a news impact score of 2.3 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 7.0 out of 10, meaning that recent news coverage is likely to have an effect on the stock's share price in the near future. Who are some of OHR Pharmaceutical's key competitors? Some companies that are related to OHR Pharmaceutical include IMMURON LTD/S (IMRN), Evoke Pharma (EVOK), Fibrocell Science (FCSC), SUMMIT THERAPEU/S (SMMT), Ceapro (CRPOF), Onconova Therapeutics (ONTX), Novelion Therapeutics (NVLN), ESSA Pharma (EPIX), Jaguar Health (JAGX), BENITEC BIOPHAR/S (BNTC), Pain Therapeutics (PTIE), Provectus Biopharmaceuticals (PVCT), Aytu Bioscience (AYTU), Nuvo Pharmaceuticals (NRIFF) and Sernova (SEOVF). What other stocks do shareholders of OHR Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other OHR Pharmaceutical investors own include Actinium Pharmaceuticals (ATNM), Synergy Pharmaceuticals (SGYP), Cytori Therapeutics (CYTX), Novavax (NVAX), BIOLINERX LTD/S (BLRX), XOMA (XOMA), Energy Transfer LP Unit (ET), TherapeuticsMD (TXMD), Onconova Therapeutics (ONTX) and Trevena (TRVN). Who are OHR Pharmaceutical's key executives? OHR Pharmaceutical's management team includes the folowing people: Dr. Jason Scott Slakter, CEO, Pres & Director (Age 61)Mr. Samuel Backenroth, CFO, VP of Bus. Devel. & Sec. (Age 35)Dr. Glenn L. Stoller M.D., Chief Scientific Officer (Age 55)Dr. Marlene Modi, Head of Preclinical & Regulatory Affairs How do I buy shares of OHR Pharmaceutical? Shares of OHRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is OHR Pharmaceutical's stock price today? One share of OHRP stock can currently be purchased for approximately $2.25. How big of a company is OHR Pharmaceutical? OHR Pharmaceutical has a market capitalization of $6.37 million. What is OHR Pharmaceutical's official website? The official website for OHR Pharmaceutical is http://www.ohrpharmaceutical.com. How can I contact OHR Pharmaceutical? OHR Pharmaceutical's mailing address is 800 THIRD AVENUE 11TH FLOOR, NEW YORK NY, 10022. The biotechnology company can be reached via phone at 212-682-8452 or via email at [email protected] MarketBeat Community Rating for OHR Pharmaceutical (NASDAQ OHRP)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 240 (Vote Outperform)Underperform Votes: 171 (Vote Underperform)Total Votes: 411MarketBeat's community ratings are surveys of what our community members think about OHR Pharmaceutical and other stocks. Vote "Outperform" if you believe OHRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OHRP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/25/2019 by MarketBeat.com StaffFeatured Article: Why is the ROA ratio important?